Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation

Medicine & Life Sciences

• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 100%
• Dasatinib 95%
• Imatinib Mesylate 78%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72%
• Cost-Benefit Analysis 59%
• Systematic Reviews 50%
• Blast Crisis 34%
• Leukemia, Myeloid, Chronic Phase 17%
• Cytogenetics 12%
• Evaluation Studies 11%
• MEDLINE 10%
• Population 9%
• National Institutes of Health (U.S.) 6%
• Congresses 6%
• Uncertainty 5%
• Leukocytes 4%
• Bone Marrow 4%
• Clinical Studies 4%
• Randomized Controlled Trials 4%
• Databases 3%
• Neoplasms 2%

Social Sciences

• evaluation 31%
• economics 29%
• costs 23%
• absence of evidence 10%
• bone marrow 10%
• adverse events 9%
• Clinical Trials 7%
• cancer 6%
• proliferation 6%
• uncertainty 5%
• inclusion 4%
• narrative 4%
• lack 3%
• health 3%
• literature 2%